235 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (235)
- Addiction (5)
- Allergy, Asthma, & Immunology (1)
- Autoimmune Disorders (3)
- Bone & Muscle (2)
- Cancer (11)
- COVID-19 (Coronavirus) (8)
- Diabetes (7)
- Ear, Nose and Throat (7)
- Endocrine & Metabolic Disease (2)
- Gastrointestinal and Digestive Diseases (3)
- Hair and Skin Disorders (2)
- Healthy Volunteers (45)
- Heart Disease (20)
- Infectious Disease (11)
- Liver Disease (13)
- Lung Disease (2)
- Neurological Disorders (31)
- Nutrition (2)
- Obesity (9)
- Obstetrics & Gynecology (10)
- Pediatrics (17)
- Psychiatric Disorders (7)
- Rehabilitation (2)
- Stroke (2)
- Transplant (12)
- Vascular Conditions (1)
Displaying 1 - 2 of 2
Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Currently Recruiting
This is a global, multicenter, placebo-controlled, phase 3 study evaluating the efficacy and safety of riliprubart in adult participants with CIDP who are refractory or had an insufficient response to standard of care (SOC) therapies, defined as Ig administered IV (IVIg) or SC (SCIg), or corticosteroids. Treatment duration will be 48 weeks. Participant must…
Condition: Cancer / Bladder Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is to determine whether using LY4052031 in a type of cancer that may have tumor cells that express a protein called Nectin-4 is safe and how well the cancer responds to the study drug. LY4052031 has not been approved by the US Food and Drug Administration (FDA). This is a first in human study and all of the risks are not fully…